

## **HEPATITIS C REFERRAL FORM**

PATIENT INFORMATION					
Patient Name:		DOB:	Sex: 🗆 M 🗆 F	Weight:	□lbs. □kg.
SSN: Phone:		Allergies:			
Address:		City:	State:	Zip:	
Emergency Contact:	Phone:	• •	Please attach demogra	aphic information	
PRESCRIBER INFORMATION					
Prescriber:	NPI:		DEA:	State Lic:	
Supervising Physician:		Practice Name:		-	
Address:		City:	State:	Zip:	
Phone: Fax:		Key Office Contact:	•	Phone:	
INSURANCE INFORMATION					
□Please attach front and back of patient's insurance card (medical and prescription)					
COPAY CARD ENROLLMENT					
□Please check if enrolling in copay card Copay ID:					
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT					
Diagnosis Code: DB18.2 DB18.1 DOther ICD 10					
Treatment naïve Treatment experienced Decompensated Cirrhosis Compensated Cirrhosis					
■ If applicable: □Co-infected HIV/HCV □HBV/HCV					
<ul> <li>Distribution and second for allowing (figure lisekie)</li> </ul>					
<ul> <li>Other and the time and the time (including OTO and the first).</li> </ul>					
Please attach the following information:					
Clinical Notes from most recent office visit.	□Viral Load – HCV-RNA (Drawn in the past 90 days)				
Genotype – Copy of lab report.	Treatment readiness assessment (if applicable)				
CBC / including ALT, AST, SCr, etc. (Drawn in the past 9	□Fibrosis Score – Attach one of the following reports:				
Urine drug screen (If applicable)					
NS5A resistance-associated polymorphisms lab (If applicable)     Transplant status					
PT/NR – Prothrombin Time and International Normalize R	atio				
PRESCRIPTION INFORMATION					
□Epclusa® OR □ generic sofosbuvir/velpatasvir (if available)					
□400 mg/100 mg tablet OR PEDIATRIC 17kg – 30kg: □200					
1 tablet PO once daily OR Other:				QTY: 1 month	Refills:
· · · · · · · · · · · · · · · · · · ·			_	<u></u>	
Harvoni® OR 🛛 generic ledipasvir/sofosbuvir (if available)					
□90 mg/400 mg tablet OR PEDIATRIC <17kg: □33.75 mg/150 mg pellet   17kg – 35kg: □45 mg/200 mg <u>pellet</u> □45 mg/200 mg <u>tablet</u>					
1 tablet/packet PO once daily <b>OR</b> Other:			_	QTY: <u>1 month</u>	Refills:
□Sovaldi® (sofosbuvir) 400 mg tablet					
1 tablet PO once daily				QTY: 1 month	Refills:
					- tomo:
Mavyret (glecaprevir and pibrentasvir) 100 mg/40 mg tablet 3 tablets PO once daily with food					5.61
				QTY: <u>1 month</u>	Refills:
□Ribavirin □ 200 mg tablet □ 200 mg capsule □Directions:					
			QTY: 1 month	Refills:	
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) 400 mg/100 mg/100 mg tablet 1 tablet PO once daily with food				OTV: 1 month	Pofille
				QTY: <u>1 month</u>	Refills:
⊐Zepatier™ (elbasvir/grazoprevir) 50 mg/100 mg tablet					
1 tablet PO once daily			QTY: <u>1 month</u>	Refills:	
NS5A resistance-associated polymorphisms:  None  M28			o Trí		
□Other:				QTY:	Refills:
Intended combination therapy duration:  B weeks  12 weeks  16 weeks  24 weeks  Other:					

## Prescriber's Signature:

□ DAW (Dispense as Written)

Date:

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through Palmetto Specialty Pharm, this prescription shall be forwarded to an eligible pharmacy.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to Palmetto Specialty Pharm or any of its subsidiaries using the contact information provided on this coversheet.